PT Wilmar Cahaya Indonesia Tbk. (IDX:CEKA)

CTI BioPharma Cash Flow Statement

Financials in millions IDR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	304,282	324,943	153,575	220,705	187,067	181,813
Depreciation & Amortization	26,331	26,861	29,636	26,665	24,885	24,478
Other Operating Activities	-340,818	-369,920	359,262	-235,502	-303,434	-34,995
Operating Cash Flow	-10,205	-18,117	542,473	11,868	-91,482	171,295
Operating Cash Flow Growth	-	-	4471.07%	-	-	-62.20%
Capital Expenditures	-24,542	-23,251	-10,601	-69,453	-56,018	-36,487
Sale of Property, Plant & Equipment	1,786	861.15	310.42	585.11	12.85	50.72
Investment in Securities	-	-55,036	-	-	-	-
Investing Cash Flow	-22,756	-77,425	-10,291	-68,868	-56,005	-36,436
Common Dividends Paid	-59,416	-59,416	-59,416	-59,416	-59,416	-59,417
Other Financing Activities	-0.08	-	-1.83	-429.59	-4.22	-15.29
Financing Cash Flow	-59,416	-59,416	-59,417	-59,845	-59,420	-59,432
Net Cash Flow	-92,377	-154,958	472,764	-116,845	-206,906	75,427
Free Cash Flow	-34,747	-41,368	531,871	-57,585	-147,499	134,809
Free Cash Flow Growth	-	-	-	-	-	-68.95%
Free Cash Flow Margin	-0.38%	-0.52%	8.39%	-0.94%	-2.75%	3.71%
Free Cash Flow Per Share	-58.40	-69.53	893.90	-96.78	-247.90	226.57
Cash Interest Paid	0.08	-	1.83	429.59	4.22	15.29
Cash Income Tax Paid	99,113	69,539	38,465	68,483	67,127	68,471
Levered Free Cash Flow	-	-129,784	490,417	-155,175	-175,229	43,371
Unlevered Free Cash Flow	-	-129,784	490,418	-154,907	-175,227	43,380
Change in Net Working Capital	-	374,515	-353,150	286,826	286,941	74,307

Source: S&P Global Market Intelligence. Standard template. Financial Sources.